跳至主要内容
临床试验/NCT02686697
NCT02686697已完成2 期

A Double-blind, Placebo-controlled Study on the Effects of Combined L-Carnosine and Cognitive Training on Cognition in Schizophrenia

Abraham Reichenberg1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2015年12月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
60
试验地点
1
主要终点
Cognitive Training Score

研究概览

简要总结

This is a double-blind placebo-controlled trial to evaluate the effects of the combination of a cognition enhancing drug, i.e carnosine, with cognitive training in patients with schizophrenia. All participants will receive the same cognitive training sessions and will be randomised to either carnosine or placebo for the duration of the combined treatment period (2 weeks). Before combined training and carnosine/placebo, there is a two-week carnosine/placebo only phase to examine the effects of carnosine alone on functioning without training.

详细描述

Compromised cognitive functioning is a core feature of schizophrenia, yet it remains a major unmet need in the treatment of schizophrenia. Current available therapeutic approaches to enhance cognition in schizophrenia - either pharmacological or non-pharmacological (for a review) have yielded, at best, only modest results with questionable retention of the cognitive benefits and generalization of the effects into functional benefit. The investigators propose a novel approach to enhance cognition in schizophrenia: combining a food supplement with cognitive training, rather than using each intervention alone.

Aim is to test the primary hypothesis that the combination of L-carnosine with cognitive training will significantly increase the performance of patients with schizophrenia on memory and learning training tasks compared to pairing cognitive training with placebo. The investigators will also test the secondary hypotheses that in the group receiving L-carnosine increased performance is due to a greater learning rate. Carnosine has antioxidant and antiglycating action and is found in food and the human body. The investigator's choice is guided by several considerations but, primarily the evidence that L-carnosine has neuroprotective effects through its antioxidant features. Briefly, the investigators propose that alterations in metabolism in several neurotransmitter systems (particularly glutamate) can both contribute to, and be modified by, oxidative stress, and therefore antioxidant administration could positively affect neurotransmitter role in synaptic plasticity, learning and memory.

Carnosine has shown some improvements in cognitive outcomes in autism (Chez et al, 2002) and schizophrenia (Chengappa et al; unpublished). Chez used oral doses of 800mg/d for 8 weeks; while the latter study used oral doses of 2000mg for 4 weeks showing positive effects. Hence this is the dose and delivery route that will be used. The investigators have opted for 4 weeks course following broadly from these two studies. Carnosine is widely available from health and food supplement shops in the UK and US retail market in highly pure form; is a naturally occurring in food and the human body; and is well-tolerated and has a benign side-effect profile, as shown from previous trials, and is therefore not associated with any potential risks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18-60, males and females.
  • DSM-IV diagnosis of schizophrenia or schizoaffective disorder documented in a medical record, confirmation by treating physician and/or treatment team, or confirmation of diagnosis by our study psychiatrist or clinical psychologist
  • Duration of illness equal to or greater than one year.
  • Patients should be clinically stable in a non-acute phase for at least 8 weeks prior to the screening visit
  • Treatment with stable doses of antipsychotic medications for at least 4 weeks prior to the screening visit.
  • Negative result in the urine pregnancy test performed during the screening visit in women of child bearing potential (not surgically sterile or 2 years postmenopausal).Women of child-bearing potential, who are sexually active, will be considered as potential participants if they are using acceptable methods of contraception, which include barrier method with spermicide, intrauterine device (IUD), steroidal contraceptive (oral, transdermal, implanted, and injected).
  • Subjects must read and write in English at a level sufficient to understand and complete study- related procedures.
  • Informed consent signed by participant

排除标准

  • DSM -IV diagnosis of alcohol or substance abuse (other than nicotine) within the last month or a DSM-IV]diagnosis of alcohol or substance dependence (other than nicotine) in the last 6 months preceding the screening visit.
  • Current treatment (within 4 weeks) with psychotropic agents known to effect cognition: amphetamines, barbiturates, MAOIs, methylphenidate, benzodiazepines.
  • Pregnant or breast-feeding women.
  • Clinically significant abnormalities on physical examination.
  • History of a serious neurological disorder or a systemic illness with known neurological complications.
  • History of significant other major or unstable metabolic, hepatic, renal, hematological, pulmonary or cardiovascular disorders.
  • Known allergy to L-carnosine
  • Unwillingness or inability to follow or comply with the procedures outlined in the protocol.

研究组 & 干预措施

L-Carnosine

Experimental

oral doses of 2000mg for 4 weeks total - 2 weeks medication phase only, and then 2 weeks combined treatment with cognitive training.

干预措施: L-Carnosine (Drug)

L-Carnosine

Experimental

oral doses of 2000mg for 4 weeks total - 2 weeks medication phase only, and then 2 weeks combined treatment with cognitive training.

干预措施: Cognitive Training (Behavioral)

Placebo

Placebo Comparator

matching placebo

干预措施: Placebo (Drug)

Placebo

Placebo Comparator

matching placebo

干预措施: Cognitive Training (Behavioral)

结局指标

主要结局

Cognitive Training Score

时间窗: 8 weeks

Cognitive Training Score will test whether the combination of L-carnosine with cognitive training will significantly increase the performance of patients with schizophrenia on memory and learning training tasks compared to pairing cognitive training with placebo.

次要结局

  • Change in Performance Advantage(8 weeks and 10 weeks)
  • Matrix Consensus Cognitive Battery (MCCB)(8 weeks)
  • The Learning Rate(8 weeks)

研究者

发起方
Abraham Reichenberg
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Abraham Reichenberg

Professor

Icahn School of Medicine at Mount Sinai

研究点 (1)

Loading locations...

相似试验